Louis Scampavia, Ph.D.
Senior Scientific Director: Department Of Molecular Medicine
Department:
SR-MM-SCAMPAVIA LAB
Business Phone:
(561) 228-2101
Business Email:
scampavia.louis@ufl.edu
About Louis Scampavia
Additional Positions:
Senior Scientific Director
2018 – Current
·
Scripps Florida Molecular Screening Facility
Associate Professor (Joint Appointment), Molecular Therapeutics
2005 – 2017
·
Scripps Research
CSO
2003 – 2005
·
FIAsolutions Inc
Principal Investigator
2001 – 2005
·
SiChrom Inc.
Related Links:
Teaching Profile
Teaching Philosophy
Scripps Research- Graduate School Co-director TRBIO 450 Drug Discovery and Development (2019-2022) Lecturer in Drug Discovery (2018)
General Chemistry 132. Seattle University, Seattle WA 2005
Chemistry 120 Principles of Chemistry University of Washington, Seattle, WA (1998-2004)
Chemistry 321 Quantitative Analysis: University of Washington, Seattle, WA (2003-1998)
Chemistry 520 Current Problems in Analytical Chemistry; University of Washington, Seattle, WA (1998-2003)
Research Profile
Progress in drug discovery is often coupled to parallel advancements in instrument technology. In our department, High Throughput Screening (HTS) robotics is employed to accelerate the drug discovery process thorough full automation of large scale screening experiments. HTS technology can be used to execute and analyze hundreds of thousand of experiments against large compound libraries to identify a few select compounds of therapeutic value. These “therapeutic leads” provide important insight and basis for the medicinal development of novel drugs for clinical application.
Research efforts are currently focused on:
— Working with collaborators to develop biological assays for HTS compatibility.
— Performing exploratory HTS campaigns for drug lead discovery.
— Technology development and instrumentation for the advancement of HTS robotics.
Collaborative efforts are coordinated with a large community of scientists and include TSRI and UF faculty, Florida researchers, and academia often funded through the National Institutes of Health, Department of Defense and private foundations.
Open Researcher and Contributor ID (ORCID)
0000-0002-7734-0105
Publications
Academic Articles
2024
Rebamipide and Derivatives are Potent, Selective Inhibitors of Histidine Phosphatase Activity of the Suppressor of T Cell Receptor Signaling Proteins.
Journal of medicinal chemistry.
67(3):1949-1960
[DOI] 10.1021/acs.jmedchem.3c01763.
[PMID] 38252624.
2023
A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.05.30.542934.
[PMID] 37398312.
2023
A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer.
Cell death & disease.
14(9)
[DOI] 10.1038/s41419-023-06145-9.
[PMID] 37735513.
2023
High throughput assay for compounds that boost BDNF expression in neurons.
SLAS discovery : advancing life sciences R & D.
28(3):88-94
[DOI] 10.1016/j.slasd.2023.02.005.
[PMID] 36842668.
2022
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells.
mBio.
13(3)
[DOI] 10.1128/mbio.00784-22.
[PMID] 35471084.
2022
High throughput screening for compounds to the orphan nuclear receptor NR2F6.
SLAS discovery : advancing life sciences R & D.
27(4):242-248
[DOI] 10.1016/j.slasd.2022.03.005.
[PMID] 35331960.
2022
Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
SLAS discovery : advancing life sciences R & D.
27(1):8-19
[DOI] 10.1016/j.slasd.2021.10.012.
[PMID] 35058179.
2022
Lead identification using 3D models of pancreatic cancer.
SLAS discovery : advancing life sciences R & D.
27(3):159-166
[DOI] 10.1016/j.slasd.2022.03.002.
[PMID] 35306207.
2022
LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipid Content of Human Cells and Protect from Ferroptosis.
ACS chemical biology.
17(6):1607-1618
[DOI] 10.1021/acschembio.2c00317.
[PMID] 35658397.
2022
Rapid deployment of inexpensive open-source orbital shakers in support of high-throughput screening.
SLAS technology.
27(3):180-186
[DOI] 10.1016/j.slast.2022.01.003.
[PMID] 35066236.
2022
Screening for modulators of autism spectrum disorder using induced human neurons.
SLAS discovery : advancing life sciences R & D.
27(2):128-139
[DOI] 10.1016/j.slasd.2022.01.004.
[PMID] 35123134.
2021
Development and Pilot Screen of Novel High Content Assay for Down Regulators of Expression of Heterogenous Nuclear Ribonuclear Protein H2.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.
55(3):265-276
[DOI] 10.33594/000000372.
[PMID] 34014051.
2021
Discovery and Optimization of Selective Inhibitors of Meprin α (Part I).
Pharmaceuticals (Basel, Switzerland).
14(3)
[DOI] 10.3390/ph14030203.
[PMID] 33671080.
2021
Discovery and Optimization of Selective Inhibitors of Meprin α (Part II).
Pharmaceuticals (Basel, Switzerland).
14(3)
[DOI] 10.3390/ph14030197.
[PMID] 33673639.
2021
Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR.
SLAS discovery : advancing life sciences R & D.
26(2):205-215
[DOI] 10.1177/2472555220962001.
[PMID] 33016182.
2021
Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel.
PLoS neglected tropical diseases.
15(11)
[DOI] 10.1371/journal.pntd.0009898.
[PMID] 34731172.
2021
Identification of Potential Modulators of the RGS7/Gβ5/R7BP Complex.
SLAS discovery : advancing life sciences R & D.
26(9):1177-1188
[DOI] 10.1177/24725552211020679.
[PMID] 34112017.
2021
Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening.
SLAS discovery : advancing life sciences R & D.
26(1):113-121
[DOI] 10.1177/2472555220945283.
[PMID] 32734807.
2021
Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay.
Bioorganic & medicinal chemistry.
42
[DOI] 10.1016/j.bmc.2021.116246.
[PMID] 34130216.
2020
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Molecular oncology.
14(8):1800-1816
[DOI] 10.1002/1878-0261.12743.
[PMID] 32533886.
2020
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
SLAS discovery : advancing life sciences R & D.
25(10):1152-1161
[DOI] 10.1177/2472555220963667.
[PMID] 33043784.
2020
Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming.
Nature chemical biology.
16(10):1052-1061
[DOI] 10.1038/s41589-020-0584-z.
[PMID] 32690944.
2020
Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.
Scientific reports.
10(1)
[DOI] 10.1038/s41598-020-67473-w.
[PMID] 32601341.
2020
Small-molecule inhibitor targeting orphan nuclear receptor COUP-TFII for prostate cancer treatment.
Science advances.
6(18)
[DOI] 10.1126/sciadv.aaz8031.
[PMID] 32494682.
2020
SYNGAP1 Controls the Maturation of Dendrites, Synaptic Function, and Network Activity in Developing Human Neurons.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
40(41):7980-7994
[DOI] 10.1523/JNEUROSCI.1367-20.2020.
[PMID] 32887745.
2019
A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-45265-1.
[PMID] 31227747.
2019
Applications for Open Source Microplate-Compatible Illumination Panels.
Journal of visualized experiments : JoVE.
(152)
[DOI] 10.3791/60088.
[PMID] 31633701.
2019
Automating a Magnetic 3D Spheroid Model Technology for High-Throughput Screening.
SLAS technology.
24(4):420-428
[DOI] 10.1177/2472630319854337.
[PMID] 31225974.
2019
Design of Microplate-Compatible Illumination Panels for a Semiautomated Benchtop Pipetting System.
SLAS technology.
24(4):399-407
[DOI] 10.1177/2472630318822476.
[PMID] 30698997.
2019
Discovery and Characterization of Two Classes of Selective Inhibitors of the Suppressor of the TCR Signaling Family of Proteins.
ACS infectious diseases.
5(2):250-259
[DOI] 10.1021/acsinfecdis.8b00238.
[PMID] 30485744.
2019
Identification of Antimalarial Inhibitors Using Late-Stage Gametocytes in a Phenotypic Live/Dead Assay.
SLAS discovery : advancing life sciences R & D.
24(1):38-46
[DOI] 10.1177/2472555218796410.
[PMID] 30142014.
2019
The Scripps Molecular Screening Center and Translational Research Institute.
SLAS discovery : advancing life sciences R & D.
24(3):386-397
[DOI] 10.1177/2472555218820809.
[PMID] 30682260.
2018
A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells.
SLAS discovery : advancing life sciences R & D.
23(8):842-849
[DOI] 10.1177/2472555218775055.
[PMID] 29750582.
2018
A High-Throughput Time-Resolved Fluorescence Energy Transfer Assay to Screen for Modulators of RGS7/Gβ5/R7BP Complex.
Assay and drug development technologies.
16(3):150-161
[DOI] 10.1089/adt.2017.839.
[PMID] 29658790.
2018
A Novel 3D Culture System for High-Throughput Hepatoxicity Screening.
BioProcess international.
16(FR 8):1-5
[PMID] 35431667.
2018
A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.
Oncogene.
37(32):4372-4384
[DOI] 10.1038/s41388-018-0257-5.
[PMID] 29743592.
2018
A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa.
SLAS discovery : advancing life sciences R & D.
23(1):55-64
[DOI] 10.1177/2472555217728489.
[PMID] 28850797.
2018
Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.
SLAS discovery : advancing life sciences R & D.
23(6):574-584
[DOI] 10.1177/2472555218766842.
[PMID] 29673279.
2018
Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
The Biochemical journal.
475(18):2941-2953
[DOI] 10.1042/BCJ20180065.
[PMID] 30068530.
2018
Dynamic changes during the treatment of pancreatic cancer.
Oncotarget.
9(19):14764-14790
[DOI] 10.18632/oncotarget.24483.
[PMID] 29599906.
2018
High-Throughput Screening for Protein Synthesis Inhibitors Targeting Aminoacyl-tRNA Synthetases.
SLAS discovery : advancing life sciences R & D.
23(2):174-182
[DOI] 10.1177/2472555217734128.
[PMID] 29020503.
2018
Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.
Assay and drug development technologies.
16(5):278-288
[DOI] 10.1089/adt.2018.849.
[PMID] 30019946.
2018
Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders.
Molecular neuropsychiatry.
3(3):141-150
[DOI] 10.1159/000481731.
[PMID] 29594133.
2018
IoT for Real-Time Measurement of High-Throughput Liquid Dispensing in Laboratory Environments.
SLAS technology.
23(5):440-447
[DOI] 10.1177/2472630318769454.
[PMID] 29649373.
2018
Using bead injection to model dispensing of 3-D multicellular spheroids into microtiter plates.
Talanta.
177:74-76
[DOI] 10.1016/j.talanta.2017.09.022.
[PMID] 29108585.
2017
A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids.
SLAS discovery : advancing life sciences R & D.
22(5):516-524
[DOI] 10.1177/2472555216686308.
[PMID] 28346088.
2017
A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel.
Assay and drug development technologies.
15(8):395-406
[DOI] 10.1089/adt.2017.810.
[PMID] 29172645.
2017
Development of an HTS-Compatible Assay for Discovery of Melanoma-Related Microphthalmia Transcription Factor Disruptors Using AlphaScreen Technology.
SLAS discovery : advancing life sciences R & D.
22(1):58-66
[DOI] 10.1177/1087057116675274.
[PMID] 27827304.
2017
Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease.
SLAS discovery : advancing life sciences R & D.
22(7):887-896
[DOI] 10.1177/2472555217689992.
[PMID] 28346094.
2017
Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
PloS one.
12(8)
[DOI] 10.1371/journal.pone.0181830.
[PMID] 28767678.
2016
An Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy Assays.
Assay and drug development technologies.
14(1):58-66
[DOI] 10.1089/adt.2015.672.
[PMID] 26669516.
2016
An Integrated Approach for Screening and Identification of Positive Allosteric Modulators of N-Methyl-D-Aspartate Receptors.
Journal of biomolecular screening.
21(5):468-79
[DOI] 10.1177/1087057116628437.
[PMID] 26838761.
2016
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.
Scientific reports.
6(1)
[DOI] 10.1038/s41598-016-0013-4.
[PMID] 28442704.
2016
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.
Antimicrobial agents and chemotherapy.
60(4):2195-208
[DOI] 10.1128/AAC.02574-15.
[PMID] 26810656.
2016
First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating M. tuberculosis.
ACS chemical biology.
11(1):172-84
[DOI] 10.1021/acschembio.5b00517.
[PMID] 26524379.
2016
Fluorometric High-Throughput Screening Assay for Secreted Phospholipases A2 Using Phospholipid Vesicles.
Journal of biomolecular screening.
21(7):713-21
[DOI] 10.1177/1087057116646742.
[PMID] 27146384.
2016
Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.
Journal of biomolecular screening.
21(8):824-31
[DOI] 10.1177/1087057116653925.
[PMID] 27280550.
2016
Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.
Molecular and cellular endocrinology.
434:176-85
[DOI] 10.1016/j.mce.2016.07.003.
[PMID] 27389877.
2016
Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation.
eLife.
5
[DOI] 10.7554/eLife.15550.
[PMID] 27435961.
2015
Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4).
Journal of biomolecular screening.
20(7):858-68
[DOI] 10.1177/1087057115581770.
[PMID] 25877150.
2015
Assay strategies for identification of therapeutic leads that target protein trafficking.
Trends in pharmacological sciences.
36(8):498-505
[DOI] 10.1016/j.tips.2015.05.004.
[PMID] 26067100.
2015
Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening.
Assay and drug development technologies.
13(1):16-24
[DOI] 10.1089/adt.2014.627.
[PMID] 25710543.
2015
Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening.
Journal of biomolecular screening.
20(1):122-30
[DOI] 10.1177/1087057114548832.
[PMID] 25163684.
2015
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
PloS one.
10(3)
[DOI] 10.1371/journal.pone.0121833.
[PMID] 25811598.
2015
Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival.
ACS chemical biology.
10(4):925-32
[DOI] 10.1021/cb500893q.
[PMID] 25602368.
2014
A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.
Assay and drug development technologies.
12(4):238-46
[DOI] 10.1089/adt.2014.576.
[PMID] 24831790.
2014
Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α and β.
Biopolymers.
102(5):396-406
[DOI] 10.1002/bip.22527.
[PMID] 25048711.
2014
Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.
Journal of biomolecular screening.
19(7):1107-15
[DOI] 10.1177/1087057114525852.
[PMID] 24619116.
2011
Monitoring of HTS compound library quality via a high-resolution image acquisition and processing instrument.
Journal of laboratory automation.
16(3):197-203
[DOI] 10.1016/j.jala.2011.02.004.
[PMID] 21609702.
2010
A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization.
Assay and drug development technologies.
8(1):96-105
[DOI] 10.1089/adt.2009.0217.
[PMID] 20035614.
2008
Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).
Journal of biomolecular screening.
13(1):17-28
[DOI] 10.1177/1087057107310806.
[PMID] 18227223.
2006
Automated method, based on micro-sequential injection, for the study of enzyme kinetics and inhibition.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
22(1):9-14
[PMID] 16429764.
2004
A novel approach for monitoring extracellular acidification rates: based on bead injection spectrophotometry and the lab-on-valve system.
The Analyst.
129(3):205-12
[PMID] 14978521.
2004
Automated affinity chromatography measurements of compound mixtures using a lab-on-valve apparatus coupled to electrospray ionization mass spectrometry.
Analytical biochemistry.
331(1):161-8
[PMID] 15246009.
2004
On-line flow cytometry for real-time surgical guidance.
Neurosurgery.
55(3):551-60; discussion 560
[PMID] 15335422.
2003
Bead injection ELISA for the determination of antibodies implicated in type 1 diabetes mellitus.
The Analyst.
128(9):1157-62
[PMID] 14529023.
2003
Micro sequential injection: automated insulin derivatization and separation using a lab-on-valve capillary electrophoresis system.
The Analyst.
128(9):1123-30
[PMID] 14529018.
2002
Automated affinity capture-release of biotin-containing conjugates using a lab-on-valve apparatus coupled to UV/visible and electrospray ionization mass spectrometry.
Analytical chemistry.
74(18):4702-8
[PMID] 12349973.
2002
Label dilution method: a novel tool for bioligand interaction studies using bead injection in the lab-on-valve format.
The Analyst.
127(9):1228-32
[PMID] 12375849.
2002
Microsequential injection: anion separations using ‘lab-on-valve’ coupled with capillary electrophoresis.
The Analyst.
127(7):898-905
[PMID] 12173647.
2002
Real-time monitoring of lactate extrusion and glucose consumption of cultured cells using a lab-on-valve system.
The Analyst.
127(12):1583-8
[PMID] 12537364.
2001
Micro sequential injection: fermentation monitoring of ammonia, glycerol, glucose, and free iron using the novel lab-on-valve system.
The Analyst.
126(3):291-7
[PMID] 11284328.
1999
Automation of functional assays by flow injection fluorescence microscopy.
Trends in biotechnology.
17(11):443-7
[PMID] 10511702.
1999
Detection of oxygen consumption of cultured adherent cells by bead injection spectroscopy.
Analytical chemistry.
71(22):5248-52
[PMID] 10575969.
1999
Experimental study of kinematic focusing. Comparison of electroinjection and sequential injection determination of copper.
Talanta.
48(2):485-90
[PMID] 18967488.
1999
From flow injection to bead injection.
Analytical chemistry.
71(7):257A-263A
[PMID] 10204028.
1999
Hydrodynamics and mass transfer of the coaxial jet mixer in flow injection analysis.
Analytical chemistry.
71(11):2199-204
[DOI] 10.1021/ac981037t.
[PMID] 21662757.
1996
Coaxial flow mixer for real-time monitoring of cellular responses in flow injection cytometry.
Cytometry.
25(2):200-4
[PMID] 8891450.
1995
A coaxial jet mixer for rapid kinetic analysis in flow injection and flow injection cytometry.
Analytical chemistry.
67(17):2743-9
[PMID] 8779410.
1994
Fast kinetic measurements and on-line dilution by flow injection cytometry.
Cytometry.
16(4):324-30
[PMID] 7527315.
Grants
Oct 2024
ACTIVE
Utilizing UF's High-throughput Screening Capacities
Role: Co-Investigator
Funding: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Sep 2024
ACTIVE
Pharmacological targeting of nascent modulators of opioid signaling
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Jul 2024
ACTIVE
High Throughput Screening to Discover Bacterial DNA Gyrase Poisoning Inhibitors
Role: Co-Investigator
Funding: TOP BIOSCIENCES
via NATL INST OF HLTH NCATS
May 2024
ACTIVE
BioRaptr Replacement Dispensers to Support High Throughput Screening
Role: Principal Investigator
Funding: NATL INST OF HLTH OD
Jan 2024
ACTIVE
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV
Role: Co-Investigator
Funding: SCRIPPS RESEARCH INST
via NATL INST OF HLTH NIDDK
Oct 2023
– Apr 2024
Altos HTS Discovery for ISR Inhibitors 640K HTS with 1 counterscreen
Role: Co-Investigator
Funding: ALTOS LABS
Oct 2023
– Apr 2024
TCAL USP11 Biochemcial FRET INH Assay 640K HTS Proprosal with 2 Counterscreens
Role: Co-Investigator
Funding: TAKEDA PHARM NORTH AMERICA
Jul 2023
– Jul 2024
Arvinas: Ataxin-2 Degraders HiBit cell based 665K HTS with 2 counterscreens
Role: Co-Investigator
Funding: ARVINAS OPERATIONS
May 2023
– Oct 2023
Lilly NPY2R AG TR-FRET cAMP High Throughput Screen Assay 880K HTS Proposal with 1 Counterscreen
Role: Co-Investigator
Funding: SCIENCE EXCHANGE
May 2023
– Oct 2023
TCAL TREM-2
Role: Co-Investigator
Funding: TAKEDA PHARM NORTH AMERICA
Apr 2023
ACTIVE
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2023
– Jan 2024
Annexon Bio -Complement C1s Protease Fluorescence INH HTS Campaign with UF Scripps 640K Deck plus 1 Counterscreen
Role: Co-Investigator
Funding: ANNEXON
Dec 2022
– Nov 2023
Kainomyx -PfMyo-A Absorbance INH HTS Campaign with UF Scripps 640K Deck plus 1 Counterscreen
Role: Co-Investigator
Funding: KAINOMYX
Oct 2022
– Dec 2023
TCAL OMA-1 FRET Biochemical INH Assay 666K SDDL HTS Proposal with 1 Counterscreen
Role: Co-Investigator
Funding: TAKEDA PHARM NORTH AMERICA
Sep 2022
– Mar 2023
Lilly AMY3R PAM TR-FRET cAMP High Throughput Screen Assay 665K HTS Proprosal with 1 Counterscreen
Role: Co-Investigator
Funding: SCIENCE EXCHANGE
via ELI LILLY AND CO
Jul 2022
– Dec 2022
TCAL OXR1 AG and PAM Ca++ High Throughput Screen Assay 665K HTS Proprosal with 2 Counterscreens
Role: Co-Investigator
Funding: TAKEDA PHARM NORTH AMERICA
Jun 2022
– Jan 2023
HEK AAV2 Induction and GFP Reporter Assay 600K HTS
Role: Co-Investigator
Funding: THERMOFISHER SCIENTIFIC
Jun 2022
– Dec 2023
Takeda TCAL GPCR HTS
Role: Co-Investigator
Funding: TAKEDA PHARM NORTH AMERICA
May 2022
ACTIVE
Midwest AViDD Center – CORE B
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via NATL INST OF HLTH NIAID
May 2022
– Apr 2024
Midwest AViDD Center – Project 3
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via NATL INST OF HLTH NIAID
Apr 2022
– Feb 2024
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022
ACTIVE
Identification of novel anthelmintics through a target-based screen of a parasite ion channel
Role: Principal Investigator
Funding: MEDICAL COLLEGE OF WISCONSIN
via NATL INST OF HLTH NIAID
Apr 2022
– Jul 2024
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity
Role: Co-Investigator
Funding: SCRIPPS RESEARCH INST
via NATL INST OF HLTH NIDA
Apr 2022
– Apr 2024
Identification of REV-ERB inverse agonists for cancer immunotherapy
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022
– Aug 2023
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV
Role: Co-Investigator
Funding: SCRIPPS RESEARCH INST
via NATL INST OF HLTH NIDDK
Apr 2022
– Jun 2023
High-Throughput Screen for the Oncoprotein MYC
Role: Co-Investigator
Funding: SCRIPPS RESEARCH INST
via NATL INST OF HLTH NCI
Apr 2022
– Mar 2023
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Apr 2022
– Sep 2022
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022
– Sep 2022
Tandem Multi-modal Plate Readers for a High Throughput Screening platform
Role: Principal Investigator
Funding: NATL INST OF HLTH OD
Apr 2022
– May 2022
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Apr 2022
– Apr 2022
Development of neutral ceramidase inhibitor tool compounds
Role: Principal Investigator
Funding: THE RES FOU FOR THE SUNY STONY BROOK UNI
via NATL INST OF HLTH NCI
Education
Doctor of Philosophy in Chemistry
1996
·
University of Washington, Seattle
Bachelor's of Science in Chemistry
1991
·
University of Washington, Seattle
Bachelor's of Science in Genetics
1979
·
University of California, Berkeley
Contact Details
Phones:
- Business:
- (561) 228-2101
Emails:
- Business:
- scampavia.louis@ufl.edu
Addresses:
- Business Mailing:
-
130 SCRIPPS WAY
JUPITER FL 33458 - Business Street:
-
Location A111
130 SCRIPPS WAY BLDG 1A1
JUPITER FL 33458